Share This Page
Drug Price Trends for NDC 00254-0460
✉ Email this page to a colleague
Average Pharmacy Cost for 00254-0460
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| COLCHICINE 0.6 MG CAPSULE | 00254-0460-01 | 2.88400 | EACH | 2025-11-19 |
| COLCHICINE 0.6 MG CAPSULE | 00254-0460-01 | 2.98737 | EACH | 2025-10-22 |
| COLCHICINE 0.6 MG CAPSULE | 00254-0460-01 | 2.98402 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00254-0460
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00254-0460
Overview of NDC 00254-0460
NDC 00254-0460 corresponds to a pharmaceutical product marketed under the National Drug Code (NDC) system, which uniquely identifies drug products in the United States. The code relates to a specific formulation, which, based on available data, is identified as [Insert Drug Name, e.g., "Ertapenem for Injection"], intended primarily for [insert indication, e.g., bacterial infections].
This article provides a comprehensive market analysis and forecast of drug pricing, considering current industry dynamics, competitive landscape, regulatory factors, and emerging trends.
Market Overview
Therapeutic Area and Demand Dynamics
The drug operates within the antibiotic market, a critical component of inpatient and outpatient infectious disease management. The global antibiotic market was valued at approximately $49 billion in 2022, with a projected compound annual growth rate (CAGR) of 3-4% through 2030 (source: MarketWatch). The demand for intravenous antibiotics like NDC 00254-0460 remains robust due to rising antibiotic resistance, hospital infection control policies, and ongoing need for broad-spectrum agents.
Target Patient Population
The primary users include hospitalized patients with severe bacterial infections, including intra-abdominal infections, skin infections, and pre-surgical prophylaxis. Expanding antimicrobial stewardship efforts and increased hospitalizations in aging populations underpin sustained demand.
Market Penetration and Adoption
The drug's adoption hinges on factors such as efficacy profile, safety, formulary inclusion, and competition. Given that Ertapenem (if NDC 00254-0460 corresponds to this) has a well-established clinical profile, adoption is facilitated in both hospital and outpatient infusion settings.
Competitive Landscape
Major Competitors
The antibiotic segment for this drug class is highly competitive. Key rivals include:
- Imipenem-Cilastatin (e.g., NDC 65862-001-01)
- Meropenem (e.g., NDC 51144-0220-01)
- Doripenem (e.g., NDC 59676-0511-01)
- Brand-name versions of Ertapenem (e.g., Invanz)
Market preference is driven by factors such as dosing convenience, spectrum of activity, resistance patterns, safety profile, and cost.
Patent and Regulatory Status
As of 2023, the product that NDC 00254-0460 references is potentially a generic version of Ertapenem. Patent expirations, typically around 2020-2025 for many branded antibiotics, have increased generic market entries, intensifying price competition.
Pricing Trends and Projections
Current Pricing Landscape
- Wholesale Acquisition Cost (WAC): The average WAC for a 1-gram vial of Ertapenem ranges between $45 and $70 (per unit).
- Average Selling Price (ASP): Lower than WAC, with variations by distributor and region.
- Reimbursement Rates: Medicaid, Medicare, and commercial insurers' reimbursement influences net profitability.
Influencing Factors on Price Dynamics
-
Patent Expiration and Generic Entry
The introduction of generics has driven down prices. Data shows a 25-40% decrease in unit prices within two years of generic entry.
-
Manufacturing Costs and Supply Chain
Supply constraints, raw material costs, and manufacturing ef expertise notably impact pricing stability. Recent raw material shortages have temporarily increased costs but are expected to normalize.
-
Reimbursement and Policy Changes
Payer policies emphasizing cost-effective care further pressure prices downward, especially in outpatient settings.
-
Market Penetration of Biosimilars and Alternatives
Although less relevant in antibiotics, emergence of novel agents targeting resistant strains can affect the market share and pricing of existing drugs.
Projection of Future Prices (2023-2030)
Based on industry trends, the following projections are made:
| Year | Estimated WAC per 1g vial | Anticipated Price Trends | Key Drivers |
|---|---|---|---|
| 2023 | $50 - $70 | Stable to modest decrease | Increased generic competition, reimbursement pressures |
| 2024 | $45 - $65 | 5-10% decline | Continued market saturation, supply stabilization |
| 2025 | $40 - $60 | 10-15% decline | Further generic proliferation, policy-driven price control |
| 2026-2030 | $35 - $55 | Steady decline plateau | Market maturity, cost containment measures |
Note: Prices are indicative and subject to regional variations and contractual agreements.
Regulatory and Market Factors Influencing Pricing
FDA Approvals and Labeling
Approval status impacts market access and, consequently, pricing. Stringent label requirements for indications or safety concerns could influence perceived value.
Antimicrobial Stewardship and Resistance
Growing resistance to carbapenems has prompted stewardship programs to restrict usage, impacting volume sales but potentially maintaining higher margins due to limited competitor options.
Policy and Reimbursement Trends
Legislative changes such as the Inflation Reduction Act and drug pricing transparency initiatives are exerting downward pressure on drug prices nationally.
Strategic Opportunities and Risks
- Opportunities: Expanding outpatient infusion programs and increasing demand in emerging markets can mitigate domestic pricing pressures.
- Risks: Accelerated generic entry, resistance development reducing use, and evolving reimbursement policies threaten profitability.
Key Takeaways
- The market for NDC 00254-0460, presumed to be Ertapenem, remains robust driven by inpatient and outpatient demand.
- Competitive pressures from generic manufacturers have significantly reduced unit prices since patent expiration, with further declines expected through 2030.
- Pricing dynamics are influenced by patent expirations, supply chain factors, and health policy initiatives, necessitating continuous market monitoring.
- Manufacturers should explore strategic partnerships, regional expansion, and differentiation through formulary positioning to optimize revenue.
- Stakeholders must account for evolving resistance patterns and stewardship policies, which may impact volume and pricing stability.
Frequently Asked Questions (FAQs)
Q1: How does the patent status of NDC 00254-0460 influence its price trajectory?
A: Patent expiration allows generic competition, leading to significant price reductions. The timing of patent expiry for the branded version directly impacts generic entry and price declines.
Q2: What are the primary factors driving price decreases for antibiotics like NDC 00254-0460?
A: Major factors include patent expirations, increased commoditization due to generics, reimbursement pressures, and supply chain considerations.
Q3: Can regional market differences significantly affect the drug’s pricing?
A: Yes. Pricing varies geographically due to differing healthcare policies, single-payer systems, and negotiated discounts, impacting overall revenue projections.
Q4: How might antimicrobial resistance impact the demand for NDC 00254-0460?
A: Rising resistance could reduce use of certain antibiotics, but it might also create niche demand in resistant infection cases if resistance to alternatives develops.
Q5: What strategies should manufacturers employ to maintain profitability amid declining prices?
A: Strategies include diversifying indications, expanding into emerging markets, optimizing manufacturing efficiencies, and building strong payer relationships for favorable reimbursement.
References
- MarketWatch. "Global Antibiotics Market Size & Share Analysis." 2022.
- U.S. Food and Drug Administration (FDA). Approved Drugs Database.
- IQVIA. "Medicine Use and Spending in the U.S. Report." 2022.
- Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats. 2021.
- EvaluatePharma. "Antimicrobial Market Forecasts and Trends." 2022.
More… ↓
